IMMUNOTHERAPY

The SURVIVE trial of the targeted vaccine SurVaxM did not meet its primary OS end point due to longer-than-expected survival with standard of care in glioblastoma but showed benefit in patients 65 years and younger.

A single blood draw 3 to 9 weeks into immunotherapy predicted survival outcomes in metastatic non–small cell lung cancer, according to a new Johns Hopkins study.

Second-line platinum plus pemetrexed produced an 11.5-month median OS and 72% disease control after first-line nivolumab/ipilimumab in pleural mesothelioma.

The FDA has granted fast track designation to PLN-101095 plus pembrolizumab for ICI-refractory advanced or metastatic solid tumors.

The individualized neoantigen therapy intismeran autogene improved recurrence-free survival over pembrolizumab alone in patients with fully resected melanoma.

An analysis found that postprogression access to effective therapy was associated with smaller OS benefits in targeted therapy trials but not in immunotherapy trials.

EIK1001, an agonist of TLR 7 and 8, is being investigated in first-line advanced melanoma in combination with pembrolizumab.

FDA approves a new rituximab biosimilar, boosting CD20 therapy options and market competition for B-cell cancers and autoimmune diseases in the US.

SER-155 led to short-term improvement in diarrhea management in patients receiving immune checkpoint inhibitors.

During a live event, Sapna Patel, MD, discussed how to sequence second-line therapy for a patient with BRAF-mutant melanoma after immunotherapy and targeted therapy.

During a live event, Amit Mahipal, MD, and participants discussed how to recognize and manage immune-related adverse events arising from combination regimens for unresectable HCC.

A PD-1/TIGIT bispecific antibody plus T-DXd yielded pathologic complete responses, avoiding need for further chemotherapy.

A combination regimen targeting LAG-3 and PD-1 did not significantly extend progression-free survival in advanced melanoma vs single-agent pembrolizumab.

Gut microbiome bacteria are linked to risk of recurrence after treatment with immunotherapy for resectable melanoma.

ODD status was granted based on tumor response rates with eftilagimod alfa and pembrolizumab of more than 3-fold above historical benchmarks from radiotherapy alone.